Effects of imipramine on anxiety and depressive-like behavior and body weight gain in rats housed in overcrowded conditions

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Long-term crowding in rats can lead to anxiety-depressive disorders. Antidepressants, including Imipramine, are used in clinical and experimental settings to correct such states. The aim of this study was to test whether Imipramine has an antidepressant and/or anxiolytic effect on the behavior of rats kept in overcrowded conditions. We studied the effect of daily (4 days before and 10 days during crowding) intraperitoneal injections of Imipramine at a dose of 10 mg/kg on the behavior in tests for anxiety (open field, light-dark, and elevated plus maze – EPM) and in forced swimming test after Imipramine withdrawal (12–15 days of overcrowding) in rats housed in overcrowded (16 rats per cage) and standard (4–5 rats per cage) conditions. Also, body weight gain on days 8 and 12 of overcrowding and the blood plasma corticosterone level on day 16 of overcrowding were assessed in the same groups of rats. Overcrowding led to activation of behavioral reactions in the light-dark and EPM tests, which did not decrease (with the exception of three indicators) after Imipramine treatment. So, Imipramine did not have a significant corrective effect in these tests on the behavior of rats kept in overcrowded conditions. In the forced swimming test under overcrowded conditions, an increase in immobility was observed, and imipramine led to the correction of this disorder. Body weight gain decreased after treatment of Imipramine in standard and overcrowded (to a greater degree) conditions, which may indicate a negative side effect of the antidepressant. The level of corticosterone in blood plasma did not differ in rats kept in overcrowded and standard conditions and did not change under the influence of Imipramine. Thus, the antidepressant Imipramine had a therapeutic effect on increased immobility in the forced swim test in rats under overcrowded conditions. This suggests that the behavioral changes observed in this test in rats under crowded conditions are depressive-like behavioral disorders. That is, imipramine had a pronounced antidepressant effect in the forced swimming test.

Full Text

Restricted Access

About the authors

E. V. Loseva

Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences

Author for correspondence.
Email: losvnd@mail.ru
Russian Federation, Moscow

N. A. Loginova

Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences

Email: losvnd@mail.ru
Russian Federation, Moscow

A. A. Potekhina

Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences

Email: losvnd@mail.ru
Russian Federation, Moscow

N. D. Broshevitskaya

Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences

Email: losvnd@mail.ru
Russian Federation, Moscow

O. V. Kurskaya

Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences

Email: losvnd@mail.ru
Russian Federation, Moscow

M. I. Zaichenko

Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences

Email: losvnd@mail.ru
Russian Federation, Moscow

K. Y. Sarkisova

Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences

Email: losvnd@mail.ru
Russian Federation, Moscow

References

  1. Лосева ЕВ (2021) Психосоциальный стресс перенаселенности (скученности): негативные последствия для организма человека и грызунов. Интеграт физиол 2: 33–40. [Loseva EV (2021) Psychosocial stress of overcrowding: negative consequences for humans and rodents. Integrat Physiol 22: 33–40. (In Russ)]. https://www.doi.org/10.33910/2687-1270-2021-2-1-33-40
  2. López-Muñoz F, Alamo C (2009) Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 15: 1563–1586. https://www.doi.org/10.2174/138161209788168001
  3. Brown WA, Rosdolsky M (2015) The clinical discovery of imipramine. Am J Psychiatr 172(5): 426–429. https://doi.org/10.1176/appi.ajp.2015.14101336
  4. Volz HP, Laux G (2022) Tricyclics: Imipramine, Clomipramine, Trimipramine (Dibenzazepines). In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C (eds) Neuropsychopharmacotherapy. Springer Cham. 1–11. https://doi.org/10.1007/978-3-319-56015-1_385-1
  5. Fayez R, Gupta V (2024) Imipramine. [Updated 2023 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557656/
  6. Campos-Cardoso R, Silva CPB, Carolino ROG, Anselmo-Franci JA, Tirapelli CR, Padovan CM (2021) Imipramine attenuates anxiety- and depressive-like effects of acute and prolonged ethanol-abstinence in male rats by modulating SERT and GR expression in the dorsal hippocampus. Behav Brain Res 408: 113295. https://doi.org/10.1016/j.bbr.2021.113295
  7. Possamai-Della T, Dal-Pont GC, Resende WR, Aguiar-Geraldo JM, Peper-Nascimento J, Quevedo J, Valvassori SS (2022) Imipramine can be effective on depressive-like behaviors, but not on neurotrophic factor levels in an animal model for bipolar disorder induced by ouabain. Mol Neurobiol 59: 7170–7181. https://doi.org/10.1007/s12035-022-03022-y
  8. Sarkisova KY, Midzianovskaia IS, Kulikov MA (2003) Depressive-like behavioral alterations and c-fos expression in the dopaminergic brain regions in WAG/Rij rats with genetic absence epilepsy. Behav Brain Res 144: 211–226. https://doi.org/10.1016/s0166_4328(03)00090_1
  9. Ramirez K, Shea DT, McKim DB, Reader BF, Sheridan JF (2015) Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance. Brain Behav Immun 46: 212–220. https://doi.org/10.1016/j.bbi.2015.01.016
  10. Ramirez K, Sheridan JF (2016) Antidepressant imipramine diminishes stress-induced inflammation in the periphery and central nervous system and related anxiety- and depressive- like behaviors. Brain Behav Immun 57: 293–303. https://doi.org/10.1016/j.bbi.2016.05.008
  11. Mavissakalian M, Perel J, Guo S (2002) Specific side effects of long-term imipramine management of panic disorder. J Clin Psychopharmacol 22: 155–161. https://doi.org/10.1097/00004714-200204000-00008
  12. Sarkisova KY, Gabova AV, Fedosova EA, Shatskova AB, Narkevich VB, Kudrin VS (2023) Antidepressant and anxiolytic effects of L-Methionine in the WAG/RIJ rat model of depression comorbid with absence epilepsy. Int J Mol Sci 24: 12425. https://doi.org/10.3390/ijms241512425
  13. Bonda C, Pawar S, Lokhande J (2017) Evaluation of antidepressant activity of tramadol in comparison with imipramine in Swiss albino mice. Int J Basic Clin Pharmacol 6: 695–699. https://doi.org/10.18203/2319-2003.ijbcp20170839
  14. Ramos A, Pereira E, Martins GC, Wehrmeister TD, Izídio GS (2008) Integrating the open field, elevated plus maze and light/dark box to assess different types of emotional behaviors in one single trial. Behav Brain Res 193: 277–288. https://doi.org/10.1016/j.bbr.2008.06.007
  15. Loseva EV, Loginova NA, Russu LI, Mezentseva MV (2022) Behavior of rats in tests for anxiety after a short intranasal injection of single-walled carbon nanotubes in two small doses. J Evol Biochem Phys 58: 1973–1986. https://doi.org/10.1134/S0022093022060254
  16. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730–732. https://doi.org/10.1038/266730a0
  17. Cryan JF, Valentino RJ, Lucki I (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29: 547–569. https://doi.org/10.1016/j.neubiorev.2005.03.008
  18. Sarkisova KYu, Kulikov MA (2006) Behavioral characteristics of WAG/Rij rats susceptible and non-susceptible to audiogenic seizures. Behav Brain Res 166: 9–18. https://doi.org/10.1016/j.bbr.2005.07.024
  19. Sarkisova K, van Luijtelaar G (2011) The WAG/Rij strain: A genetic animal model of absence epilepsy with comorbidity of depression. Prog Neuropsychopharmacol Biol Psychiatr 35: 854–876. https://doi.org/10.1016/j.pnpbp.2010.11.010
  20. Loginova NA, Loseva EV, Sarkisova KYu, Kudrin VS (2023) Effects of interferon-α on depressive-like behavior and brain neurochemistry in rats housed in standard and overcrowding conditions. J Evol Biochem Phys 59: 2005–2021. https://doi.org/10.1134/S0022093023060108
  21. Broshevitskaya ND, Pavlova IV, Zaichenko MI, Gruzdeva VA, Grigoryan GA (2021) Effects of early proinflammatory stress on anxiety and depression-like behavior in rats of different ages. Neurosci Behav Physiol 51: 390–401. https://doi.org/10.1007/s11055-021-01083-5
  22. Calvano SE, Reynolds RW (1984) Circadian fluctuations in plasma corticosterone, corticosterone-binding activity and total protein in male rats: possible disruption by serial blood sampling. Endocr Res 10(1): 11–25. https://doi.org/10.1080/07435808409046762. PMID: 6745208
  23. D'Agostino J, Vaeth GF, Henning SJ (1982) Diurnal rhythm of total and free concentrations of serum corticosterone in the rat. Acta Endocrinol (Copenh) 100(1): 85–90. https://doi.org/10.1530/acta.0.1000085. PMID: 7202315
  24. Kudryavtseva NN, Shurlygina AV, Galyamina AG, Smagin DA, Kovalenko IL, Popova NA, Nikolin VP, Ilnitskaya SI, Melnikova EV, Trufakin VA (2019) Immunopathology of mixed anxiety/depression disorders: an experimental approach to studies of immunodeficiency states (review). Neurosci Behav Physiol 49: 384–398. https://doi.org/10.1007/s11055-019-00745-9
  25. Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 Suppl 1: 2–19. https://doi.org/10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2–4
  26. Latanov AV, Korshunov VA, Maiorov VI, Serkov AN (2019) Serotonin and Dopamine in Biological Models of Depression. Neurosci Behav Physiol 49: 987–996. https://doi.org/10.1007/s11055-019-00828-7
  27. Pilipović I, Stojić-Vukanić Z, Leposavic GM (2023) Adrenoceptors as potential target for add-on immunomodulatory therapy in multiple sclerosis. Pharmacol Therap 243(Pt 1): 108358. https://doi.org/10.1016/j.pharmthera.2023.108358
  28. Uarquin DG, Meyer JS, Cardenas FP, Rojas MJ (2016) Effect of overcrowding on hair corticosterone concentrations in juvenile male Wistar rats. J Am Assoc Lab Anim Sci 55(6): 749–755. PMID: 27931312; PMCID: PMC5113875
  29. Gądek-Michalska A, Bugajski A, Tadeusz J, Rachwalska P, Bugajski J (2017) Chronic social isolation in adaptation of HPA axis to heterotypic stress. Pharmacol Rep 69: 1213–1223. https://doi.org/10.1016/j.pharep.2017.08.011
  30. Gavrilov VV, Onufriev MV, Moiseeva YV, Alexandrov YI, Gulyaeva NV (2022) Chronic social isolation stress and crowding in rats have different effects on learning an operant behavior and the state of the hypothalamo-hypophyseal-adrenocortical system. Neurosci Behav Physiol 52: 698–704. https://doi.org/10.1007/s11055-022-01295-3
  31. Хлебникова НН, Крупина НА (2017) Экспериментальное тревожно-депрессивное состояние у крыс, вызванное неонатальным действием ингибитора дипептидилпептидазы-IV дипротина А: эффекты имипрамина. Патол физиол экспер терапия 61(4): 4–12. [Khlebnikova NN, Krupina NA (2017) Experimental anxiety-depressive state in rats caused by neonatal exposure to the inhibitor of dipeptidyl peptidase IV, diprotin A: effects of imipramine. Pathol Physiol Exp Therapy 61(4): 4–12. (In Russ)]. https://doi.org/10.25557/IGPP.2017.4.8517
  32. Knyazeva SI, Loginova NA, Loseva EV (2012) Anxiety level and body weight changes in rats living in overpopulated cages. Bull Exp Biol Med 154(1): 3–6. https://doi.org/10.1007/s10517-012-1860-z
  33. Mogensen J, Pedersen TK, Holm S (1994) Effects of chronicimipramine on exploration, locomotion, and food/water intake in rats. Pharmacol Biochem Behav 47(3): 427–435. https://doi.org/10.1016/0091-3057(94)90139-2
  34. Лосева ЕВ, Логинова НА, Потехина АА, Федосова ЕА, Саркисова КЮ (2022) Воздействие имипрамина на тревожно-депрессивное поведение и привес массы тела у крыс при стандартном и скученном содержании. Интеграт физиол Всерос конф междунар участием, тезисы докл СПб. Ин-т физиол им ИП Павлова РАН 7–9 дек. 125. [Loseva EV, Loginova NA, Potekhina AA, Fedosova EA, Sarkisova KYu (2022) Effect of imipramine on anxiety-depressive behavior and body weight gain in rats under standard and crowded conditions. Integrative physiology. All-Russian confer with internat participat, abstracts of reports. St. Petersburg. Pavlov Institute Physiol RAS. December 7–9. 125. (In Russ)]. ISBN 978-5-4386-2232-1
  35. Loseva EV, Loginova NA, Potekhina AA, Fedosova EA, Sarkisova KYu, Broshevitskaya ND, Zaichenko MI (2023) Influence of the antidepressant imipramine on behavior in tests for anxiety and depression, body weight gain and blood corticosterone level in rats kept at subchronic overcrowding. Neuroscie Med Psychol. ХIX Internat Interdisciplin Congr, Abstracts Rep. Sudak, Crimea, Russia, May 30 – June 10. MAKS-Press LLC Moscow. 179–180. (In Russ, in Engl). https://doi.org/10.29003/m3292.sudak.ns2023-19/179-180

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Body weight gain (g) in groups of rats kept under standard conditions (St) or overcrowded conditions (Oc), after daily i.p. administration of saline solution (SS) or imipramine (IM) at a dose of 10 mg/kg. Groups of rats kept under St conditions: St+SS – control after SS administration; St+IM – after IM administration. Groups of rats kept under Oc conditions: Oc+SS – control after SS administration; Oc+IM – after IM administration. The ordinate axis shows body weight gain values ​​in all groups 8 and 12 days after crowding of rats from the Oc+SS and Oc+IM groups. Data are presented as mean ± SEM: *tp < 0.1, *p < 0.05, **p < 0.01, ***p < 0.001 compared to the group indicated by the short vertical line at the end of the horizontal line (group comparison according to the Newman–Keuls test). In addition, individual values ​​of body weight gain for each rat are given (circles to the right of the bars indicating the corresponding groups).

Download (105KB)
Indexing metadata
3. Fig. 2. Behavioral indices in the light-dark test in groups of rats kept under standard conditions (St) or overcrowded conditions (Oc), three days after the cessation of daily (14 days) i.p. administration of saline (S) or imipramine (IM) at a dose of 10 mg/kg. Groups of rats kept under St conditions: St+S – control after administration of SS, white column; St+IM – after administration of IM, light gray column). Groups of rats kept under Oc conditions: Oc+S – control after administration of SS, dark gray column; Oc+IM – after administration of IM, black column. (a) – Light box, total duration of visits, s. (b) – Light box, average duration of visit, s. (c) – Peeping out, number of acts. (d) – Pilling out, number of acts. (e) – Rears, total duration, s. (f) – Rear, average duration, s. (g) – Sniffing, total duration, s. (h) – Sniffing, average duration of act, s. Data are presented as mean ± SEM: *ttp < 0.2, *tp < 0.1, *p < 0.05, **p < 0.01, ***p < 0.001 compared to the group indicated by the short vertical line at the end of the horizontal line (group comparison according to the Newman–Keuls test). In addition, individual values ​​for each rat are given (circles to the right of the columns indicating the corresponding groups).

Download (397KB)
Indexing metadata
4. Fig. 3. Behavioural indices in the elevated plus maze (EPM) test in groups of rats kept under standard conditions (St) or overcrowded conditions (Oc), four days after the cessation of daily (14 days) i.p. administration of saline (S) or imipramine (IM) at a dose of 10 mg/kg. Groups of rats kept under St conditions: St+S – control after administration of SS, white column; St+IM – after administration of IM, light grey column). Groups of rats kept under Oc conditions: Oc+S – control after administration of SS, dark grey column; Oc+IM – after administration of IM, black column. (a) – center, total duration of visits, s. (b) – Enclosed arms, number of visits, s. (c) – Sniffing, number of acts. (d) – Sniffing, total duration, s. (e) – Rears, number. (f) – Rear, average duration, s. (g) – Handing, total duration, s. (h) – Peeping out, number of acts. Data are presented as mean ± SEM: *ttp < 0.2, *tp < 0.1, *p < 0.05, **p < 0.01, ***p < 0.001 compared to the group indicated by the short vertical line at the end of the horizontal line (group comparison according to the Newman–Keuls test). In addition, individual values ​​for each rat are given (circles to the right of the columns indicating the corresponding groups).

Download (390KB)
Indexing metadata
5. Fig. 4. Behavioral indices in the forced swimming test in groups of rats kept under standard conditions (St) or overcrowded conditions (Oc), four days after the cessation of daily (14 days) i.p. administration of saline (S) or imipramine (IM) at a dose of 10 mg/kg. Groups of rats kept under St conditions: St+S – control after administration of SS, white column; St+IM – after administration of IM, light gray column. Groups of rats kept under Oc conditions: Oc+S – control after administration of SS, dark gray column; Oc+IM – after administration of IM, black column. (a) – duration of the first episode of active swimming, s. (b) – Latensity of the first episode of immobility, s. (c) – Total immobility time, s. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 compared to the group indicated by the short vertical bar at the end of the horizontal line (group comparison according to the Newman–Keuls test). In addition, individual values ​​of the parameters for each rat are given (circles to the right of the columns indicating the corresponding groups).

Download (174KB)
Indexing metadata

Copyright (c) 2025 Russian Academy of Sciences

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».